A public tracker of how long each country takes to adopt new evidence
Measure and publish, for every practice-changing result, how long it takes before most eligible patients in each country and hospital actually receive it.
The 17-year 'bench to bedside' figure is a slogan, not a measurement. Using structured treatment data and registry linkage, the time from publication to 50 percent uptake among eligible patients can be computed per country, region and centre for each practice change. The proposal funds a public dashboard of these diffusion metrics, updated quarterly, to make slow adoption visible and comparable.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.
- Weak real-world evidence and registries · We do not reliably know what happens to patients after approval, so we cannot tell which drugs deliver in practice.
Pages like this
not linked directly; found by shared links- IdeaMake a population cancer registry a condition of every cancer aid programme
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries.
- JournalCA: A Cancer Journal for Clinicians
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results).
- IdeaRecord and publish the symptom-to-diagnosis interval for every cancer, by hospital
Shares SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries.
- IdeaAutomatic weekly linkage of cancer registries to deaths, prescriptions and imaging
Shares SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries.
- IdeaA public dashboard of research money per death for every cancer
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results), Knowledge reaches practice too slowly.
- IdeaA national late-effects registry linking treatment exposures to outcomes decades later
Shares SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries.
- IdeaCheap long-term survival follow-up by linking trial participants to registries
Shares SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries.
- IdeaSet trial enrolment targets from who actually gets the disease, and publish progress live
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results).